TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT03992027

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: CF-CBT: A Cognitive-Behavioral Skills-Based Program to Promote Emotional Well-Being for Adults wtih Cystic Fibrosis
Description: CF-CBT is an 8-session program introducing cognitive-behavioral coping skills for managing stress, and for prevention and treatment of anxiety and depression. The content of the program was developed to address stressors related to coping with cystic fibrosis. Participants will receive a patient workbook, and meet with a trained member of the CF team (interventionist) who will guide them through learning and practicing coping skills during 8 weekly sessions.

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Waitlist Control
Description: Participants receive usual care for 3 months followed by CF-CBT. CF-CBT is an 8-session program introducing cognitive-behavioral coping skills for managing stress, and for prevention and treatment of anxiety and depression. The content of the program was developed to address stressors related to coping with cystic fibrosis. Participants will receive a patient workbook, and meet with a trained member of the CF team (interventionist) who will guide them through learning and practicing coping skills during 8 weekly sessions.
Study: NCT06461936

Intervention type: DRUG
Intervention: Sintilimab
Description: Patient receives first adjuvant PD-1monoclonal antibody 2-4 weeks postoperatively, 200mg IV over 21 days for 9 cycles.

Intervention type: DRUG
Intervention: Sintilimab
Description: Patient receives first adjuvant PD-1monoclonal antibody 2-4 weeks postoperatively, 200mg IV over 21 days for 9 cycles.

Intervention type: DRUG
Intervention: Lenvatinib
Description: Lenvatinib is initiated orally 2-4 weeks postoperatively for about 6 months.
Study: NCT00994461

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Celecoxib
Description: Celecoxib 100mg tablet twice a day with meal for 2 weeks
Study: NCT02520063

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Letrozole
Description: A dose of 2.5 mg of letrozole will be given orally once each day until one day before surgery. This drug is commercially available and is not provided by the study.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Letrozole
Description: A dose of 2.5 mg of letrozole will be given orally once each day until one day before surgery. This drug is commercially available and is not provided by the study.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Letrozole
Description: A dose of 2.5 mg of letrozole will be given orally once each day until one day before surgery. This drug is commercially available and is not provided by the study.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Letrozole
Description: A dose of 2.5 mg of letrozole will be given orally once each day until one day before surgery. This drug is commercially available and is not provided by the study.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Everolimus
Description: The dose of everolimus will be escalated from 5 mg to 10 mg daily depending upon the cohort in Phase I. It is administered as an oral pill to be taken once daily up until four weeks prior to surgery.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Everolimus
Description: The dose of everolimus will be escalated from 5 mg to 10 mg daily depending upon the cohort in Phase I. It is administered as an oral pill to be taken once daily up until four weeks prior to surgery.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Everolimus
Description: The dose of everolimus will be escalated from 5 mg to 10 mg daily depending upon the cohort in Phase I. It is administered as an oral pill to be taken once daily up until four weeks prior to surgery.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Everolimus
Description: The dose of everolimus will be escalated from 5 mg to 10 mg daily depending upon the cohort in Phase I. It is administered as an oral pill to be taken once daily up until four weeks prior to surgery.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TRC105
Description: The dose for TRC105 is either 15 or 10 mg/kg to be given intravenously every two weeks and continued until four weeks prior to surgery.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TRC105
Description: The dose for TRC105 is either 15 or 10 mg/kg to be given intravenously every two weeks and continued until four weeks prior to surgery.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TRC105
Description: The dose for TRC105 is either 15 or 10 mg/kg to be given intravenously every two weeks and continued until four weeks prior to surgery.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TRC105
Description: The dose for TRC105 is either 15 or 10 mg/kg to be given intravenously every two weeks and continued until four weeks prior to surgery.
Study: NCT04431596

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Forearm cooling
Description: forearm immersion will be performed for active cooling assessment.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Mist-fan cooling
Description: A mist-fan will be placed in front of the participant for active cooling.
Study: NCT02031887

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: formula with synbiotics

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: formula without synbiotics
Study: NCT03206320

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lidocaine Topical
Description: Comparison of lidocaine topical gel with lidocaine infiltration and with no local anesthesia in reducing needle insertion and injection pain

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lidocaine Topical
Description: Comparison of lidocaine topical gel with lidocaine infiltration and with no local anesthesia in reducing needle insertion and injection pain
Study: NCT02811861

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lenvatinib

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lenvatinib

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Everolimus

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sunitinib
Study: NCT02172755

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BIA 2-093
Description: During the whole study, subjects were to receive a single 600 mg dose of BIA 2-093 (Phase A) followed by 600 mg BIA 2-093 once daily for 8 days in Phase B. Phase B was to begun 96 hours post-Phase A dose.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BIA 2-093
Description: During the whole study, subjects were to receive a single 600 mg dose of BIA 2-093 (Phase A) followed by 600 mg BIA 2-093 once daily for 8 days in Phase B. Phase B was to begun 96 hours post-Phase A dose.
Study: NCT00686166

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: cetuximab
Description: Chemotherapy cycle 1: Cetuximab, 400 mg/m\^2, IV, Day 1; Cetuximab, 250 mg/m\^2, IV, Days 8,15,22,29~Chemotherapy+ Radiation Cycle 2: Cetuximab, 250 mg/m\^2, IV, Days 50,57,64,71,78

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: capecitabine
Description: Chemotherapy Cycle 1: Capecitabine, 1650 mg/m\^2/day, PO, Monday-Friday (Day 1-35)~Chemotherapy+ Radiation Cycle 2: Capecitabine, 1650 mg/m\^1, PO, Monday-Friday (Day 50-84)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: oxaliplatin
Description: Chemotherapy Cycle 1: Oxaliplatin, 50 mg/m\^2, IV, Days 1,8,15,22,29~Chemotherapy+ Radiation Cycle 2: Oxaliplatin, 50 mg/m\^2, IV, Days 50,57,71,78

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: therapeutic surgical procedure
Description: Surgical resection

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: radiation therapy
Description: IMRT (intensity-modulated radiation therapy)
Study: NCT03474042

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GLPG2737
Description: GLPG2737 oral capsules administered twice daily for 28 days on top of Orkambi.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo oral capsules administered twice daily for 28 days on top of Orkambi.
Study: NCT04263883

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Study or Experimental Group
Description: 3D PCO to make mirror image therapy (reverse posture training) during the patient walking on motorized treadmill, This way of functional training will deliver via the use of the adjustable cervicothoracic orthosis during the patient walking at approximately 2-3 miles per hour on a standard, motorized treadmill. The brace will reverse the abnormal posture according to the 3D posture analysis data. To facilitate tissue remodeling by reverse posture training, this called mirror image traction.then the ambulatory exercises by using treadmill will be performed while the patient's mirror image posture will be held by the adjustable orthosis, ambulatory exercises for 20 minutes by using treadmill based on Harrison et al., approach, this program will be repeated 2-3 times /week for 10weeks.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Study or Experimental Group
Description: 3D PCO to make mirror image therapy (reverse posture training) during the patient walking on motorized treadmill, This way of functional training will deliver via the use of the adjustable cervicothoracic orthosis during the patient walking at approximately 2-3 miles per hour on a standard, motorized treadmill. The brace will reverse the abnormal posture according to the 3D posture analysis data. To facilitate tissue remodeling by reverse posture training, this called mirror image traction.then the ambulatory exercises by using treadmill will be performed while the patient's mirror image posture will be held by the adjustable orthosis, ambulatory exercises for 20 minutes by using treadmill based on Harrison et al., approach, this program will be repeated 2-3 times /week for 10weeks.
Study: NCT00433498

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: carboplatin
Description: Should be given according to local practice but suggested doses and schedules are provided in the protocol.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: carboplatin
Description: Should be given according to local practice but suggested doses and schedules are provided in the protocol.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: cisplatin
Description: Should be given according to local practice but suggested doses and schedules are provided in the protocol.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cisplatin
Description: Should be given according to local practice but suggested doses and schedules are provided in the protocol.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: etoposide phosphate
Description: Day 1: given by IV, days 2 and 3 given by IV or oral. Dose should be given according to local practice but suggested doses and schedules are provided in the protocol.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: etoposide phosphate
Description: Day 1: given by IV, days 2 and 3 given by IV or oral. Dose should be given according to local practice but suggested doses and schedules are provided in the protocol.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: pravastatin sodium
Description: 40mg daily oral tablet taken for a maximum of 2 years
Study: NCT03036124

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dapagliflozin
Description: 10 mg or 5 mg tablets given once daily, per oral use.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo matching dapagliflozin 10 mg or 5 mg.
Study: NCT00508066

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bupivacaine
Description: Bupivacaine 0.25 - 0.5% @ 4ml/hr for 72 hours

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Normal Saline
Description: Normal Saline, 4ml/hour for 72 hours.
Study: NCT05113628

Intervention type: DIAGNOSTIC_TEST
Group type: SHAM_COMPARATOR
Intervention: methylene blue identification
Description: After ligation of the middle thyroid vein and the upper pole of the thyroid, the thyroid lobe was retracted medially and diluted methylene blue (0.5 ml methylene blue 2% was diluted by 5ml normal saline) was sprayed over the lower thyroid pole and the perilobar area. This area contains structures including recurrent laryngeal nerve, parathyroid glands, and inferior thyroid vessels which were observed After spraying.~The vocal cord mobility was assessed intraoperatively by the anesthesiologist at time of extubation. The serum calcium was measured on the 2nd postoperative day. There was no routine use of postoperative calcium supplementation. Hypocalcemia was defined when the serum calcium level was less than 8 mg/dl.
Study: NCT00994461

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Loxoprofen
Description: Loxoprofen 60mg tablet three times a day with meal for 2 weeks

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo tablet three times a day with meal for 2 weeks
Study: NCT03055312

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: TPC
Description: Conventional chemotherapy(choose a):~TX:(Docetaxel 75mg/m2 iv day1 and Capecitabine 950mg/m2 po twice daily days 1-14)every 3 weeks.~GT:(Paclitaxel 175mg/m2 iv day1 and Gemcitabine 1250mg/m2 iv days 1 \& days 8)every 3 weeks.~GC:(Gemcitabine 1000mg/m2 on days 1 \& days 8 and Carboplatin by Area Under Curve (AUC) 2 iv on days 1 \& days 8) every 3 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bicalutamide 150 mg
Description: Bicalutamide 150mg/day,every 28 days
Study: NCT03990883

Intervention type: DEVICE
Group type: OTHER
Intervention: Princess Filler Lidocaine
Description: correction of nasolabial folds

Intervention type: DEVICE
Group type: OTHER
Intervention: Princess Filler Lidocaine
Description: correction of nasolabial folds
Study: NCT03422250

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: transcranial direct current stimulation (tDCS)
Description: 10 daily 25-minutes tDCS sessions over two weeks.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: transcranial direct current stimulation (tDCS)
Description: 10 daily 25-minutes tDCS sessions over two weeks.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: transcranial direct current stimulation (tDCS)
Description: 10 daily 25-minutes tDCS sessions over two weeks.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: transcranial direct current stimulation (tDCS)
Description: 10 daily 25-minutes tDCS sessions over two weeks.
Study: NCT02173665

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 1356 BS - Powder in bottle (PIB)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 1356 BS - Tablet

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Study: NCT04224077

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Optimisation of DTI sequences
Description: Optimisation of DTI sequences in the study of lumbar roots by MRI
Study: NCT03045666

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Exercise program
Description: patients who are stable on Macitentan therapy (received in both groups before enrollment) and will exercise at a pulmonary rehabilitation program twice a week for 12 weeks
Study: NCT03816904

Intervention type: OTHER
Intervention: Blood samples
Description: Blood samples before the introduction of chemotherapy
Study: NCT05517317

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Autologous BMMC transplantation
Description: One administration of autologous bone marrow mononuclear cells via the hepatic artery
Study: NCT01483274

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Vaccine
Description: Decitabine followed by donor lymphocyte infusing and Dendritic cells pulsed with MAGE-A1, MAGE-A3, and NEY-ESO-1 vaccine

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Vaccine
Description: Decitabine followed by donor lymphocyte infusing and Dendritic cells pulsed with MAGE-A1, MAGE-A3, and NEY-ESO-1 vaccine
Study: NCT04400851

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sintilimab
Description: Patients were enrolled by the design of phase I study standard. Sintilimab was divided into three dosage levels: 1 mg / kg, 3 mg / kg, and 10 mg / kg. The first level of sintilimab was followed by dose escalation
Study: NCT01659606

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: alemtuzumab
Description: Conditioning: alemtuzumab 0.2 mg/kg/dose IV/SC x 5 doses

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine
Description: fludarabine 30 mg/m2/dose IV x 6 doses

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclosporins

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mycophenolate mofetil

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tacrolimus
Study: NCT02329171

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Imiquimod
Description: Imiquimod 5% cream will be administered in a vaginal applicator, containing 12,5 mg of imiquimod (one sachet). The cream will be self-administered three times per week, by use of a vaginal applicator.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: LLETZ
Description: Standard treatment consists of a LLETZ procedure, in which excision of the transformation zone and macroscopic lesions is performed by a monopolar loop electrode, under local anaesthesia. The excision is usually performed in two or three steps, depending on the size of the lesions.
Study: NCT00237458

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lacosamide
Description: Dosage: Lacosamide up to 400 mg/day;~Dosage form: Film-coated tablets;~Dosage Frequency and Duration: Two times per day; 9.5 years
Study: NCT03073031

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Tablet: Samsung Galaxy Tab A
Study: NCT04707521

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: 3M tape ship-shaped combined with strap fixing method
Description: During fixation, the endotracheal intubation and dental pad were located in the center of the mouth, and one end of one piece of medical cloth adhesive was pasted on the patient's cheek near the side. When it reached one side of the mouth, the endotracheal intubation and dental pad were wound around twice, and then the other side of the adhesive tape was pasted on the cheek opposite the side from the other side of the mouth,The other is fixed in reverse with the same sticking method, and the two pieces of adhesive tape are finally crossed and fixed at the corners of the mouth.Finally, fasten it with a lacing
Study: NCT01725022

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Home Care
Description: This is the interventional arm where patients receive the transplant care in their homes.
Study: NCT00800995

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: SOD

Intervention type: DIETARY_SUPPLEMENT
Group type: SHAM_COMPARATOR
Intervention: Sham
Study: NCT03831113

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Magnitude Group
Description: Dose reductions will alternate between 1mg or 2 mg weekly until the subject is no longer taking buprenorphine or is at the lowest tolerable dose.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Frequency Group
Description: Dose reductions of 2 mg will occur alternate between once weekly to biweekly until the subject is no longer taking buprenorphine or is at the lowest tolerable dose.
Study: NCT01925950

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: orBec

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT04719780

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Emotionally Focused Therapy for Individuals
Description: Emotionally Focused Therapy for Individuals (EFIT) is formulated as a transdiagnostic treatment to treat depression and anxiety, adapted from the well-studied Emotionally Focused Therapy. EFIT has been formulated as an attachment-based alternative to current cognitive approaches (e.g., Cognitive Behavioural Therapy). The strong evidence for insecure attachment as an underlying factor in psychopathology, especially depression and anxiety, positions this theory well as a foundational principle to support psychotherapy for these conditions.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Self-Help CBT Training
Description: Individuals in the Waitlist Control Group will receive access to MoodGym, a self-help online program that helps teach CBT interventions. This access will last 15 weeks and is self-driven, meaning participants proceed through the program at their own pace.
Study: NCT02316600

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: smart insole
Description: smart insole to encourage the frail elderly person's physical activity and to monitor key parameters of frailty
Study: NCT01202578

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: tympanostomy tube
Description: tympanostomy tube delivery system
Study: NCT02541513

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: paliparidone
Description: All patients will begin receiving oral paliperidone 3 mg daily for three days, beginning on Day 5 of the inpatient phase. All patients will receive an injection of Paliperidone 150 mg injection on Day 8 of the inpatient phase. Patients will receive monthly 150 mg injection for the next 3 months.
Study: NCT01891916

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Extensively hydrolyzed casein formula + LGG
Description: Extensively hydrolyzed formula containing Lactobacillus GG
Study: NCT00066248

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cyproheptadine hydrochloride
Description: Receive 0.25mg/kg cyproheptadine hydrochloride once daily for 4 weeks. If subject responds to treatment (stable or increased weigh), go off study. If subject does not respond (loses weigh), subject will switch to10 mg/lg/day of megestrol acetate for 4 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cyproheptadine hydrochloride
Description: Receive 0.25mg/kg cyproheptadine hydrochloride once daily for 4 weeks. If subject responds to treatment (stable or increased weigh), go off study. If subject does not respond (loses weigh), subject will switch to10 mg/lg/day of megestrol acetate for 4 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: megestrol acetate
Description: Receive 0.25mg/kg cyproheptadine hydrochloride once daily for 4 weeks. If subject responds to treatment (stable or increased weigh), go off study. If subject does not respond (loses weigh), subject will switch to10 mg/lg/day of megestrol acetate for 4 weeks.
Study: NCT04063189

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Clarithromycin Lenalidomide Dexamethasone (BiRd) Regimen
Description: Clarithromycin 500mg，po，bid，d1-21; Lenalidomide 25mg，po，daily，d1-21 (dose according to creatinine clearance rate); Dexamethasone 20mg，po，daily，d1-2, 8-9,15-16, 22-23